

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/836,544	04/17/2001	Brian Seed	11-88L	6823	
23713	7590 04/21/2005		EXAM	EXAMINER	
GREENLEE WINNER AND SULLIVAN P C			DIBRINO, MARIANNE NMN		
4875 PEARL	EAST CIRCLE				
SUITE 200			ART UNIT	PAPER NUMBER	
BOULDER,	BOULDER, CO 80301		1644		

DATE MAILED: 04/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

091836,544

	$\psi \psi \psi$		L
APPLICATION NO.			
CONTR	OL NO		

FILING DATE

FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

ART UNIT

PAPER

4152005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Please find below a communication from the EXAMINER in charge of this application

This application fails to comply with 37 C.F.R. 1.821-1.825 for the reason(s) listed on the Notice to comply with the sequence rules. The applicants are required to either submit a new CRF and Sequence Listing or a letter authorizing the use of the sequence listing filed with the prior application, along with a statement that the sequences in the two cases are identical.

37 C.F.R. 1.821 (e) A copy of the "Sequence Listing" referred to in paragraph © of this section must also be submitted in computer readable form in accordance with the requirements of § 1.824. The computer readable form is a copy of the "Sequence Listing" and will not necessarily be retained as part of the patent application file. If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified.

(f) In addition to the paper copy required by paragraph © of this section and the computer readable form required by paragraph (e) of this section, a statement that the content of the paper and computer readable copies are the same must be submitted with the computer readable form. Such a statement must be a verified statement if made by a person not registered to practice before the Office.

Any inquiry concerning this communication should be directed to Examiner Marianne DiBrino, Art Unit 1644, whose telephone number is 571-272-0842.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Marianne DiBrino, Ph.D.

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600

PTO-90C (Rev.04-03)

Notice to Comply

Application No. 09/836,544	Applicant(s) SEED ET AL	
Examiner Marianne DiBrino	Art Unit	
•	1644	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the	requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
⊠ the	7. Other: Applicant must provide a SEQ ID NO for the sequence appearing on page 65 at lines 25-26 of specification.
Αp	plicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
⊠ into	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
app	A statement that the content of the paper and computer readable copies are the same and, where licable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 25(d).
For	questions regarding compliance to these requirements, please contact:
For For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support
	Technical Assistance703-287-0200

To Purchase Patentin Software......703-306-2600 PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY